{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:25:39Z","timestamp":1787617539691,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jaad.2023.11.068","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T02:48:17Z","timestamp":1705978097000},"page":"1232-1239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial"],"prefix":"10.1016","volume":"90","author":[{"given":"Loretta","family":"Fiorillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Belloni-Fortina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Armesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneet K.","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoshun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Arkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2023.11.068_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.11.068_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in children and adolescents: diagnosis, management and comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jaad.2023.11.068_bib3","first-page":"121","article-title":"Psoriasis in children","volume":"6","author":"Pinson","year":"2016","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"10.1016\/j.jaad.2023.11.068_bib4","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: update on treatments and challenges-a review","volume":"33","author":"Hebert","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2023.11.068_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000450826","article-title":"Systematic review of health-related quality of life in adolescents with psoriasis","volume":"232","author":"Gonzalez","year":"2016","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.jaad.2023.11.068_bib6","first-page":"1057","article-title":"Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients","volume":"8","author":"Kelly","year":"2021","journal-title":"Children (Basel)"},{"issue":"5","key":"10.1016\/j.jaad.2023.11.068_bib7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/pde.12416","article-title":"Effect of age at diagnosis on chronic quality of life and long-term outcomes of individuals with psoriasis","volume":"32","author":"Kim","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.11.068_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2011.11.948","article-title":"Risks of developing psychiatric disorders in pediatric patients with psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2023.11.068_bib9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2017.0499","article-title":"Pediatric psoriasis comorbidity screening guidelines","volume":"153","author":"Osier","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.11.068_bib10","series-title":"Otezla [package insert]","year":"2023"},{"issue":"2","key":"10.1016\/j.jaad.2023.11.068_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","article-title":"Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study","volume":"82","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.11.068_bib12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.11.068_bib13","doi-asserted-by":"crossref","unstructured":"Papp K, Reich K, Leonardi CL, et\u00a0al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73(1):37-49.","DOI":"10.1016\/j.jaad.2015.03.049"},{"issue":"6","key":"10.1016\/j.jaad.2023.11.068_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224001087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224001087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:51:09Z","timestamp":1732611069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0190962224001087"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.11.068","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.11.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}